BCM
IBB icon

BlueCrest Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

BlueCrest Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-9,000
Closed -$782K – 948
2016
Q1 		$782K Buy
+9,000
New +$805K 0.05% 425
2015
Q1 		– Sell
-30,000
Closed -$3.03M – 679
2014
Q4 		$3.03M Buy
+30,000
New +$2.92M 0.1% 209

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BlueCrest Capital Management's IBB Position: Q4 2019 in Review

BlueCrest Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2019, closing a stake of 14,967 shares — an estimated $1.49M sold.

BlueCrest Capital Management first reported a position in IBB in Q3 2015 and held it in 12 quarters. The position peaked at $27.7M in Q3 2017. 710 funds tracked by Wall St. Rank hold IBB as of Q4 2019.

  • BlueCrest Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 14,967 iShares Biotechnology ETF shares in Q4 2019, an estimated $1.49M.
  • BlueCrest Capital Management first reported a position in iShares Biotechnology ETF in Q3 2015 and held it in 12 quarters.
  • BlueCrest Capital Management's iShares Biotechnology ETF position peaked at $27.7M in Q3 2017.
  • 710 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.